Compare Bristol-Myers Squibb Co (BMY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Jones Lang LaSalle Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.91 (market cap $116.30B), while Jones Lang LaSalle Inc trades at $333.49 (market cap $14.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.8× Jones Lang LaSalle Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| BMY | JLL | |
|---|---|---|
Market Cap | $116.30B | $14.94B |
Sector | Health | Real Estate |
52-Week High | $62.37 | $358.66 |
52-Week Low | $42.60 | $248.95 |
Enterprise Value | $152.24B | $18.48B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JLL trades at $321.95, down 0.77% today, with a bullish technical outlook supported by moving averages and strong support near $319. The company shows robust fundamentals with revenue growth to $26.12B in 2025 and consistent earnings beats, while valuation ratios like P/E of 17.32 and P/S of 0.58 appear reasonable. Recent news highlights significant refinancing deals and positive AI workforce studies, reinforcing business momentum.
JLL offers a favorable risk-reward profile with a consensus price target of $405.50 implying 26% upside, backed by analyst optimism and improving cash flows. Key risks include economic sensitivity to real estate cycles and competitive pressures. The stock presents a growth opportunity driven by operational execution and market leadership, though investors should monitor debt levels and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
